Polycaprolactone / Tricalcium Phosphate (PCL/TCP) v Titanium Orbital Implant : Randomised Trial

NCT ID: NCT01119144

Last Updated: 2014-04-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-04-30

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hypothesis: Polycaprolactone / Tricalcium Phosphate Orbital (PCL / TCP) Implant is as effective in the reconstruction of the Orbital walls as Titanium Mesh implant.

In this study we will be conducting a randomised trial to compare implants made of 2 materials for Orbital reconstruction

* Polycaprolactone / Tricalcium Phosphate (PCL / TCP)
* Titanium

Patients to be recruited :

* 80 randomised equally into the 2 groups
* age range: 21 - 70
* includes orbital wall defects from trauma, after osteotomies
* excludes patients with Diabetes Mellitus, known allergies to polycaprolactone \& its analogues, know allergies to Tricalcium Phosphate \& its analogues, infections generalised \& around the orbital region

Trial Duration: April 2010 - March 2015

Follow up:

* postoperative 1 week, 1 month, 3 months, 6 months, and 12 months
* Computer Tomographic (CT) scan of Orbits immediate postoperative and at 12 months appointment

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypothesis: Polycaprolactone / Tricalcium Phosphate (PCL / TCP) Orbital Implant is as effective in the reconstruction of the Orbital walls as Titanium Mesh

In this study we will be conducting a randomised trial to compare implants made of 2 materials for Orbital reconstruction

* Polycaprolactone / Tricalcium Phosphate (PCL / TCP)
* Titanium

Patients to be recruited :

* 80 randomised equally into the 2 groups
* age range: 21 -70
* includes orbital wall defects from trauma confirmed by Computer Tomographic (CT) scans, after osteotomies
* excludes patients with Diabetes Mellitus, known allergies to polycaprolactone \& its analogues, know allergies to Tricalcium Phosphate \& its analogues, infections generalised \& around the orbital region

Trial Duration : April 2010 - March 2015

Follow up:

* postoperative 1 week, 1 month, 3 months, 6 months, and 12 months
* Computer Tomographic (CT) scan of Orbits immediate postoperative and at 12 months appointment
* all patients will be seen \& assessed in the Plastic \& Ophthalmology outpatient clinics by Principal Investigator (PI) and collaborators

End point :

* endpoint for follow-up is 12 months
* all patients are assessed for assessed for diplopia, enophthalmos, exophthalmos, visual acuity, mobility of the globe, contour symmetry
* all patients will have a Computer Tomographic (CT) scan of the orbits at 12 months to assess the bony orbit \& orbital volume
* patients will be discharged from follow up at 12 months if asymptomatic
* patients with complications will exit the protocol \& will be treated on their merits eg. infection - removal of implant, etc

Data Management :

* maintained by the Principal Investigator (PI) under repository of the Research \& Development Office, National Healthcare Group (NHG) / National University Health Systems (NUHS), Singapore
* no data will be released without the permission of the Principal Investigator (PI) \& the Research \& Development Office, National Healthcare Group (NHG) / National University Health Systems (NUHS), Singapore

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fractures Enophthalmos Diplopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Polycaprolactone / Tricalcium Phosphate

Polycaprolactone / Tricalcium Phosphate group to assess efficacy of new implant

Group Type EXPERIMENTAL

Polycaprolactone / Tri-Calcium Phosphate

Intervention Type DEVICE

Orbital implant for reconstruction of the orbital walls

Control

Control group with titanium mesh

Group Type ACTIVE_COMPARATOR

Titanium Mesh

Intervention Type DEVICE

Titanium mesh for comparison to Polycaprolactone / Tri-Calcium Phosphate (PCL / TCP) mesh

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Polycaprolactone / Tri-Calcium Phosphate

Orbital implant for reconstruction of the orbital walls

Intervention Type DEVICE

Titanium Mesh

Titanium mesh for comparison to Polycaprolactone / Tri-Calcium Phosphate (PCL / TCP) mesh

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Osteomesh Tri-Calcium Phosphate (TCP) Titanium Orbital mesh

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 21 y - 70 y
* both males / females included
* orbital fractures
* defect after orbital osteotomies

Exclusion Criteria

* patient refusal
* infection around the orbit / generalised infection
* Diabetes mellitus
* allergies to polycaprolactone \& its analogues
* allergies to titanium
Minimum Eligible Age

21 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National University Hospital, Singapore

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

National University Hospital / National Unviersity of Singapore

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Thiam Chye Lim, MD

Role: PRINCIPAL_INVESTIGATOR

Natioanl University Hospital, Singapore

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National University Hospital

Singapore, Singapore, Singapore

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Singapore

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Thiam Chye Lim

Role: primary

Eileen Hing

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

D / 08 / 465

Identifier Type: REGISTRY

Identifier Source: secondary_id

NUHS/SUR/2010/1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effectiveness of 3D Bone Matrix in Cranioplasty
NCT06792864 ENROLLING_BY_INVITATION PHASE3